Clinical Trial Update: Mobile-Directly Observed Therapy on Adherence to Hydroxyurea [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mobile directly observed therapy to improve adherence to hydroxyurea in patients with sickle cell disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Muhimbili University of Health and Allied Sciences | Conditions: Sickle Cell Anaemia | Phase 2 | Status: COMPLETED